fluzoparib: Clinical Trials

45 trials of fluzoparib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 unknown, 11 recruiting, 9 not yet recruiting, 6 completed. 45 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 245Unknown 17, Recruiting 11, Not yet recruiting 9, Completed 6, Suspended 1, Terminated 1
Phase 17Unknown 3, Completed 2, Not yet recruiting 1, Recruiting 1

Follow fluzoparib: new trials by email Literature Review of fluzoparib trials Research Report on fluzoparib

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)
Fluzoparib, Physician choice - Breast Cancer
Phase 2Not yet recruitingFudan University3342026-03-312026-01-20
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
Fluzoparib - Ovarian Cancer
Phase 2Not yet recruitingJinhua Zhou432026-02-282026-02-03
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage
Phase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1002025-12-312025-08-26
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
Fluzoparib with Temozolomide - Glioblastoma
Phase 2Not yet recruitingTongji Hospital302025-07-102025-07-02
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
irinotecan liposome (II) + temozolomide + fluzoparib - Ewing Sarcoma
Phase 2RecruitingSun Yat-sen University292025-04-152025-05-31
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. - Metastatic Castration-resistant Prostate Cancer
Phase 2RecruitingJianbin Bi402024-11-272025-05-14
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Fluzoparib, Bevacizumab, Paclitaxel - Ovarian Cancer, Fallopian Tube Cancer
Phase 2RecruitingQilu Hospital of Shandong University1052024-11-272024-12-16
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Fluzoparib, Dalpiciclib - Ovarian Cancer
Phase 2Not yet recruitingFudan University302024-09-012024-08-14
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
Fluzoparib, Everolimus, Fulvestrant - Breast Cancer
Phase 2UnknownFudan University2602024-08-212024-08-19
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Fluzoparib - Ovarian Cancer
Phase 2UnknownQilu Hospital of Shandong University482024-06-182024-11-27
Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer
Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib - Platinum-sensitive Relapsed Ovarian Cancer
Phase 2Not yet recruitingThe First Hospital of Jilin University222024-06-012024-06-06
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Fluzoparib, Camrelizumab, paclitaxel (albumin bound) - Endometrial Carcinoma, TP53 Mutation
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1172024-05-102024-05-14
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Adebrelimab plus Fluzoparib - Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
Phase 2Not yet recruitingZhejiang Cancer Hospital402024-04-162024-02-12
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingRisen (Suzhou) Pharma Tech Co., Ltd.3062024-01-112025-07-25
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Fluzoparib, Fluzoparib+Apatinib - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary
Phase 2UnknownGuangxi Medical University802023-12-102023-12-07
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) - PARP Inhibitor for Esophageal Squamous Cell Carcinoma
Phase 2UnknownChongqing University Cancer Hospital1202023-11-012023-09-26
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fluzoparib, Apatinib - Relapsed Ovarian Cancer
Phase 2Not yet recruitingJin Li542023-10-302023-10-13
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Fluzoparib Capsules, Bevacizumab - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary
Phase 2Not yet recruitingSun Yat-sen University442023-10-182023-10-02
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Fluzoparib, QL1101 - Ovarian Cancer
Phase 2UnknownYongpeng Wang252023-07-272023-07-28
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab - NSCLC, Non-small Cell Lung Cancer
Phase 2UnknownSun Yat-sen University602023-07-012023-07-06

Showing 20 of 45. Sign in to see all of them.

Conditions studied

Ovarian Neoplasms (10)  ·  Breast Neoplasms (5)  ·  Fallopian Tube Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Sarcoma (3)  ·  Triple Negative Breast Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Neoplasm Metastasis (2)  ·  Small Cell Lung Carcinoma (2)  ·  Carcinoma, Renal Cell (1)  ·  Colorectal Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Glioblastoma (1)  ·  Kenny-Caffey syndrome, Type 1 (1)

Sponsors

Fudan University (12)  ·  Jiangsu HengRui Medicine Co., Ltd. (5)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3)  ·  Sun Yat-sen University (3)  ·  Qilu Hospital of Shandong University (2)  ·  Chongqing University Cancer Hospital (1)  ·  Fujun Zhang (1)  ·  Guangxi Medical University (1)  ·  Huazhong University of Science and Technology (1)  ·  Jianbin Bi (1)  ·  Jin Li (1)  ·  Jinhua Zhou (1)  ·  Risen (Suzhou) Pharma Tech Co., Ltd. (1)  ·  Ruijin Hospital (1)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)

Countries

China (36)

Top investigators

Beihua Kong (1)  ·  Chaosu Hu, M.D. (1)  ·  Fujun Zhang, Ph.D,M.D (1)  ·  Haitao Wang (1)  ·  Haiyan Liu (1)  ·  Hongqian Guo, Phd (1)  ·  Jianbin Bi, Doctor (1)  ·  Jin Wang, MD (1)  ·  Junxiang Wen, PhD, MD (1)  ·  Kun Song (1)  ·  Ning-Ning Lu, Dr. (1)  ·  Qiyuan Bao, PhD, MD (1)  ·  Weibin Zhang, PhD, MD (1)  ·  Xianjun Yu, M.D. (1)

Results publications

PMID 32719455, PMID 33570247, PMID 35105939, PMID 37185961, PMID 38290515, PMID 38362377, PMID 39232761